CA2466415C - Pgc-1.beta., a novel pgc-1 homologue and uses therefor - Google Patents

Pgc-1.beta., a novel pgc-1 homologue and uses therefor Download PDF

Info

Publication number
CA2466415C
CA2466415C CA2466415A CA2466415A CA2466415C CA 2466415 C CA2466415 C CA 2466415C CA 2466415 A CA2466415 A CA 2466415A CA 2466415 A CA2466415 A CA 2466415A CA 2466415 C CA2466415 C CA 2466415C
Authority
CA
Canada
Prior art keywords
pgc
nucleic acid
activity
polypeptide
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2466415A
Other languages
English (en)
French (fr)
Other versions
CA2466415A1 (en
Inventor
Bruce M. Spiegelman
Jiandie Lin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of CA2466415A1 publication Critical patent/CA2466415A1/en
Application granted granted Critical
Publication of CA2466415C publication Critical patent/CA2466415C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA2466415A 2001-11-09 2002-11-08 Pgc-1.beta., a novel pgc-1 homologue and uses therefor Expired - Lifetime CA2466415C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33812601P 2001-11-09 2001-11-09
US60/338,126 2001-11-09
PCT/US2002/035869 WO2003042362A2 (en) 2001-11-09 2002-11-08 PGC-1β, A NOVEL PGC-1 HOMOLOGUE AND USES THEREFOR

Publications (2)

Publication Number Publication Date
CA2466415A1 CA2466415A1 (en) 2003-05-22
CA2466415C true CA2466415C (en) 2020-01-21

Family

ID=23323511

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2466415A Expired - Lifetime CA2466415C (en) 2001-11-09 2002-11-08 Pgc-1.beta., a novel pgc-1 homologue and uses therefor

Country Status (6)

Country Link
US (4) US7091006B2 (de)
EP (1) EP1525323B1 (de)
JP (1) JP2005514921A (de)
AU (1) AU2002352558A1 (de)
CA (1) CA2466415C (de)
WO (1) WO2003042362A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004015415A1 (ja) * 2002-08-08 2004-02-19 Japan Science And Technology Agency 薬剤スクリーニング方法
WO2006014529A1 (en) * 2004-07-07 2006-02-09 Dana-Farber Cancer Institute, Inc. Methods and compositions for treating obesity
CA2579093A1 (en) * 2004-09-03 2006-03-09 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating pgc-1.alpha. to treat neurological diseases and disorders
CA2584331A1 (en) 2004-10-22 2006-05-04 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating pgc-1.beta. to treat lipid-related diseases and disorders
JPWO2006098314A1 (ja) * 2005-03-15 2008-08-21 アステラス製薬株式会社 新規糖取り込み活性化剤及びそのスクリーニング法
BRPI0500959A (pt) * 2005-03-23 2006-11-21 Unicamp uso farmacológico de inibidor da expressão da proteìna coativador 1 alfa do receptor ativado por proliferador do peroxisoma (pgc-1(alfa)) para o tratamento de diabetes mellitus, resistência à insulina e sìndrome metabólica, seu composto e sua composição farmacêuticos
BRPI0711174A2 (pt) * 2006-05-03 2011-08-23 Novartis Ag uso de compostos orgánicos
CA2695505A1 (en) * 2007-08-06 2009-02-12 Burnham Institute For Medical Research Znf206: a novel regulator of embryonic stem cell self-renewal and pluripotency
US8476227B2 (en) 2010-01-22 2013-07-02 Ethicon Endo-Surgery, Inc. Methods of activating a melanocortin-4 receptor pathway in obese subjects
US9044606B2 (en) 2010-01-22 2015-06-02 Ethicon Endo-Surgery, Inc. Methods and devices for activating brown adipose tissue using electrical energy
RU2631597C2 (ru) 2011-07-15 2017-09-25 Нусерт Сайенсиз, Инк. Композиции и способы модулирования метаболических путей
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
SG10201709195TA (en) 2012-11-13 2017-12-28 Nusirt Sciences Inc Compositions and methods for increasing energy metabolism
EP2954905B1 (de) 2012-12-26 2018-05-02 Toshihiro Nakajima Screening-verfahren für einen regulator der pgc-1beta proteinfunktion
CN105228627B (zh) 2013-03-15 2018-07-13 纽斯尔特科学公司 亮氨酸和烟酸降低脂质水平
KR20160119863A (ko) 2014-02-27 2016-10-14 뉴서트 사이언시스, 인크. 간 지방증의 감소 또는 예방을 위한 조성물 및 방법
US10092738B2 (en) 2014-12-29 2018-10-09 Ethicon Llc Methods and devices for inhibiting nerves when activating brown adipose tissue
US10080884B2 (en) 2014-12-29 2018-09-25 Ethicon Llc Methods and devices for activating brown adipose tissue using electrical energy
WO2017184583A1 (en) 2016-04-19 2017-10-26 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Anaplerotic agents for treatment of disorders of propionate and long chain fat metabolism
WO2018093839A1 (en) * 2016-11-15 2018-05-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Therapy for mitochondrial fatty acid beta-oxidation and transport disorders
KR102660375B1 (ko) * 2020-12-15 2024-04-26 (주)디마인 PGC-1α 유래 펩타이드 유도체 및 그를 포함하는 화장료 조성물
CN117568398B (zh) * 2023-09-19 2024-06-04 新乡医学院 一种PGC-1α基因敲除小鼠构建心律失常动物模型的方法及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
DE122007000007I2 (de) 1986-04-09 2010-12-30 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
JPH04501510A (ja) 1989-07-25 1992-03-19 セル　ジェネシス，インコーポレイティド 普遍的なドナー細胞及びキメラ性哺乳類宿主のための相同性組換え
MA22668A1 (fr) 1990-07-10 1993-07-01 Smithkline Beecham Corp Procede de preparation d'oxamides .
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
WO1994010300A1 (en) 1992-10-30 1994-05-11 The General Hospital Corporation Interaction trap system for isolating novel proteins
GB9517780D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
GB9517779D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
US6426411B1 (en) * 1997-05-30 2002-07-30 Dana-Farber Cancer Institute PGC-1, a novel brown fat pparγ coactivator
US6166192A (en) 1997-05-30 2000-12-26 Dana-Farber Cancer Institute PGC-1, a novel brown fat PPARγ coactivator
WO2001054472A2 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
AU2001292561A1 (en) * 2000-09-01 2002-03-13 Hyseq, Inc. Nucleic acids and polypeptides
GB0022670D0 (en) * 2000-09-15 2000-11-01 Astrazeneca Ab Molecules
WO2002032938A2 (en) * 2000-10-17 2002-04-25 Bayer Aktiengesellschaft Regulation of human pgc-1-like protein
CA2584331A1 (en) * 2004-10-22 2006-05-04 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating pgc-1.beta. to treat lipid-related diseases and disorders

Also Published As

Publication number Publication date
US20030124598A1 (en) 2003-07-03
US20120094293A1 (en) 2012-04-19
CA2466415A1 (en) 2003-05-22
JP2005514921A (ja) 2005-05-26
AU2002352558A1 (en) 2003-05-26
US8445233B2 (en) 2013-05-21
US7354738B2 (en) 2008-04-08
US20070009933A1 (en) 2007-01-11
EP1525323A2 (de) 2005-04-27
WO2003042362A2 (en) 2003-05-22
EP1525323B1 (de) 2015-01-21
US7091006B2 (en) 2006-08-15
WO2003042362A3 (en) 2005-03-03
US8105774B2 (en) 2012-01-31
EP1525323A4 (de) 2009-08-05
US20080261224A1 (en) 2008-10-23
WO2003042362A8 (en) 2004-05-21

Similar Documents

Publication Publication Date Title
US8105774B2 (en) PGC-1β, PGC-1 homologue and uses therefor
US20090098569A1 (en) Novel PGC-1 Isoforms and Uses Therefor
US20020173636A1 (en) 66784, a novel human potassium channel and uses therefor
US20020081658A1 (en) 18610, a novel human transient receptor and uses thereof
US20020123098A1 (en) 55063, a novel human NMDA family member and uses thereof
WO2001077331A9 (en) Human trp-like calcium channel protein-2 (tlcc-2)
US20020081651A1 (en) 26649, a novel human GTPase activating molecule and uses therefor
US20020123097A1 (en) 63760, a novel human transporter and uses thereof
US20020123094A1 (en) 57250, a novel human sugar transporter family member and uses thereof
US20020081696A1 (en) 32529, a novel human guanine nucleotide exchange factor family member and uses thereof
WO2001074854A2 (en) 32449, a putative human transporter and uses thereof
US20020086357A1 (en) 32591, a novel human GTPase activating molecule and uses therefor
WO2002026983A2 (en) 56115, a novel human twik potassium channel and uses therefor
US20020177148A1 (en) FBH58295FL, a novel human amino acid transporter and uses thereof
US20030049727A1 (en) 25658, a novel human calcium channel subunit and uses thereof
WO2001081416A2 (en) Human ion channel and uses thereof

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20221108